Company: ARWR
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0001628280-25-017844
Chunk: 0

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Financial Officer

On, April 9, 2025 Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “ Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025 (the “ Effective Date”). Mr. Myszkowski has served as the Company’s Chief Financial Officer since 2009, and the Company extends its gratitude to Mr. Myszkowski for his years of service and contributions to the Company. Mr. Myszkowski’s decision to retire was not the result of any disagreement with the Company.

Following the Effective Date, Mr. Myszkowski will serve as an employee adviser and provide transition services, as requested by the Company, to facilitate an effective transition of his job responsibilities to his successor, until January 31, 2026 (the "Transition Period"). In consideration for such services, Mr. Myszkowski will receive (i) a base salary at an annual rate of $200,000 through the end of the Transition Period, subject to his continued employment, (ii) continued eligibility to participate in the Company’s medical, dental and life insurance benefit plans through the end of the Transition Period, subject to continued employment, and (iii) continued vesting of certain outstanding equity awards.

Appointment of Chief Financial Officer

On April 9, 2025, the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company, effective as of May 13, 2024, until the earliest of Mr. Apel's removal, termination, or resignation from such office.

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024. Prior to joining Walgreens Boots Alliance, he served in various roles at Bayer, a diversified global Healthcare, Crop Science and Consumer Health company, including most recently as Chief Financial Officer for Bayer in the U. S. from 2016 through 2019. Other significant roles in his nearly 20 year career at Bayer include Chief Financial Officer for Bayer Canada and Global Head of Accounting for the Bayer Healthcare Segment, based in Germany. He has served on the boards of the Biotechnology Innovation Organization (BIO) and the Organization for International Investment, and as a